SCHEMBL6503556

SCHEMBL6503556

CCOC(=O)N(C)c1ccc(Cn2c(C)nc3ccc(-c4cccc(C(=O)O)c4)cc32)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.42
ALOX5AP P20292 1/20 0.41
EIF4EBP1 Q13541 2/20 0.37
VDR P11473 2/20 0.37
NR1H4 Q96RI1 2/20 0.37
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492014 0.93 SIRT2 (0.42) PPARGSIRT2SIRT1
SCHEMBL6498502 0.89 ALOX5AP (0.37) PPARGALOX5APEIF4EBP1NPC1CASP3
SCHEMBL6497415 0.84 PPARG (0.52) PPARGALOX5APEIF4EBP1ALDH1A1MAPT
SCHEMBL6489299 0.84 PPARG (0.45) PPARGALOX5APEIF4EBP1VDRNR1H4
SCHEMBL6491734 0.83 PPARG (0.53) PPARGALOX5APEIF4EBP1VDR
SCHEMBL6493004 0.82 PDE2A (0.47) PPARGALOX5APNPC1RAB9ASIRT2
SCHEMBL6921089 0.81 ALDH1A1 (0.44) PPARGALOX5APEIF4EBP1VDRNR1H4
SCHEMBL6487796 0.80 PPARG (0.52) PPARGSMN1; SMN2SIRT2SIRT1
SCHEMBL6491416 0.79 PPARG (0.41) PPARGALOX5APHPGDKDM4EALDH1A1
SCHEMBL6307363 0.78 PPARG (0.51) PPARGALOX5APALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PPARG 233/4885ALOX5AP 4663/4885EIF4EBP1 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.